English
norskBlar i forfatter "Sundstrøm, Stein Harald"
Viser treff 1-9 av 9
-
Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer
(Journal article; Tidsskriftartikkel; Peer reviewed, 2016-08-23)<b>Background:</b> Many patients with limited disease small cell lung cancer (LD SCLC) suffer from comorbidity. Not all patients with comorbidity are offered standard treatment, though there is little evidence for such a policy. The aim of this study was to investigate whether patients with comorbidity had inferior outcomes in a LD SCLC cohort. <br><b>Material and methods:</b> We analyzed patients ... -
Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group
(Journal article; Tidsskriftartikkel; Peer reviewed, 2013-08-20)Background: The palliative role of chemoradiation in the treatment of patients with locally advanced, inoperable non-small-cell lung cancer stage III and negative prognostic factors remains unresolved.<p> <p>Methods: Patients not eligible for curative radiotherapy were randomised to receive either chemoradiation or chemotherapy alone. Four courses of intravenous carboplatin on day 1 and oral ... -
How Do Elderly Poor Prognosis Patients Tolerate Palliative Concurrent Chemoradiotherapy for Locally Advanced NoneSmall Cell Lung Cancer Stage III? A Subset Analysis From a Clinical Phase III Trial
(Journal article; Tidsskriftartikkel; Peer reviewed, 2015-05)In a phase III trial of patients with unresectable stage III nonesmall-cell lung cancer and a poor prognosis, palliative concurrent chemoradiotherapy (CRT) provided a significantly better outcome than chemotherapy alone, except among performance status 2 patients. The results of the present exploratory subgroup analysis indicate that elderly patients with poor prognosis can also experience ... -
Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of Mesothelioma
(Journal article; Tidsskriftartikkel; Peer reviewed, 2012)Pemetrexed, a multi-folate inhibitor combined with a platinum compound is the first-line treatment of malignant mesothelioma, but median survival is still one year. Intrinsic and acquired resistance to pemetrexed is common, but its biological basis is obscure. Here we report for the first time a genome-wide profile of acquired resistance in the tumour from an exceptional case with advanced pleural ... -
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: A subset analysis from a randomized clinical phase III trial
(Journal article; Tidsskriftartikkel; Peer reviewed, 2015-11-20)Introduction: Poor prognosis patients with bulky stage III locally advanced non–small-cell lung cancer may not be offered concurrent chemoradiotherapy (CRT). Following a phase III trial concerning the effect of palliative CRT in inoperable poor prognosis patients, this analysis was performed to explore how tumor size influenced survival and health-related quality of life (HRQOL).<p> <p>Methods: ... -
Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer
(Journal article; Tidsskriftartikkel; Peer reviewed, 2015-10-23)<br>BACKGROUND: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small cell lung cancer (LD SCLC). Twice daily TRT is well documented, but not universally implemented - probably mainly due to inconvenience and concerns about toxicity. A schedule of three-week hypofractionated TRT is a commonly used alternative. This is the first randomized trial ... -
Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
(Journal article; Tidsskriftartikkel; Peer reviewed, 2018-02)Background/Aim: <br>There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and <br>Methods: <br>Patients ... -
Tumour size reduction after the first chemotherapy-course and outcomes of chemoradiotherapy in limited disease small-cell lung cancer
(Journal article; Tidsskriftartikkel; Peer reviewed, 2016-10-15)Objectives: <br> Concurrent chemotherapy and thoracic radiotherapy (TRT) is recommended for limited disease small-cell lung cancer (LD SCLC). TRT should start as early as possible, often meaning with the second course due to patient referral time and the fact that TRT planning takes time. Early assessment of response to the first course of chemotherapy may be a useful way to individualise treatment. ... -
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group
(Journal article; Tidsskriftartikkel; Peer reviewed, 2012-07-03)BACKGROUND: Platinum-based doublet chemotherapy is the standard first-line treatment for advanced non-small cell lung cancer (NSCLC), but earlier studies have suggested that non-platinum combinations are equally effective and better tolerated. We conducted a national, randomised study to compare a non-platinum with a platinum combination.<p> <p>METHODS: Eligible patients had stage IIIB/IV NSCLC ...
